BioCardia

BioCardia submitted its CardiAMP autologous cell therapy to Japan's PMDA for clinical consultation, marking a significant step toward potential regulatory approval in the key Japanese market.

BioCardia has completed enrollment and dosing of the low-dose cohort in its CardiALLO Phase I/II trial, targeting ischemic heart failure patients with elevated markers of heart stress and inflammation.

The myocardial infarction therapeutics pipeline is robust, featuring over 45 companies developing more than 50 potential drugs.

BioCardia has commercially launched its Morph DNA steerable introducer, designed for enhanced control in biotherapeutic delivery, particularly in cell-therapy clinical trials.

BioCardia's CardiAMP HF Phase 3 trial results will be presented at the American College of Cardiology (ACC) 2025 Scientific Sessions.

Genprex presented positive preclinical data for Reqorsa, a gene therapy targeting Ras inhibitor-resistant lung cancer, mesothelioma, and glioblastoma, showing increased TUSC2 uptake in tumor cells.

Shuttle Pharmaceuticals has enrolled the first patient in its Phase 2 clinical trial of ropidoxuridine for glioblastoma at the UVA Cancer Center.

BioCardia has completed the CardiAMP HF trial, a Phase III study assessing its autologous cell therapy for heart failure with reduced ejection fraction (HFrEF).

BioCardia has completed the Phase III CardiAMP HF trial, evaluating autologous cell therapy for heart failure with reduced ejection fraction (HFrEF).

BioCardia has completed the final follow-up visit in its Phase III CardiAMP HF trial, which assesses the CardiAMP Cell Therapy System for heart failure with reduced ejection fraction (HFrEF).